CAPR on XNAS, Health Care, Capricor Therapeutics Inc, job postings
Measures activity, not value. Not investment advice.
Shares up 29% in a month after falling 74% in six months, while 32% of shares sit short.
BadFree cash flow of -$132.7M over 12 months, against $197.6M cash
WatchNews ran 55 articles in seven days, 12.2 times its usual week
Written by AI from the data on this page, 22 Nov 2026. Not investment advice.
Profile and fundamentals
From its SEC filings, 12 months to 30 Sep 2026
Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.
expected around 11 Mar 2027 (an estimate: a year ago it reported on 12 Mar 2026)
Revenue and net income per quarter. Quarter to 30 Sep 2026: net loss $42.7M.
31 Dec 2021RevenueNet incomeNet losstallest bar $42.7M30 Sep 2026
See the numbers
Quarter to
Revenue
Net income
30 Sep 2026
–
-$42.7M
30 Jun 2026
–
-$40.7M
31 Mar 2026
–
-$33.9M
31 Dec 2025
–
-$30.2M
30 Sep 2025
–
-$24.6M
30 Jun 2025
–
-$25.9M
31 Mar 2025
–
-$24.4M
31 Dec 2024
$11.1M
-$7.1M
30 Sep 2024
$2.3M
-$12.6M
30 Jun 2024
$4.0M
-$11.0M
31 Mar 2024
$4.9M
-$9.8M
31 Dec 2023
$12.1M
-$762K
30 Sep 2023
$6.2M
-$6.4M
30 Jun 2023
$3.9M
-$7.4M
31 Mar 2023
$3.0M
-$7.8M
31 Dec 2022
$960K
-$7.7M
30 Sep 2022
$1.6M
-$6.4M
30 Jun 2022
–
-$7.1M
31 Mar 2022
–
-$7.8M
31 Dec 2021
–
-$6.2M
Fundamentals, 12 months to 30 Sep 2026
Measure
Latest
Year before
Peer median
RevenueiSales over the last 12 months reported.
–
–
Revenue growthiRevenue of the last 12 months compared with the 12 months before.
–
+11%
Net incomeiProfit after all costs and taxes over the last 12 months reported. Negative is a loss.
-$147.5M
-$82.0M
EPS (diluted)iEarnings per share: net income divided by the shares, counting options and convertibles. Left blank when the figures as filed do not fit today's share count (after a split).
-$2.64
-$1.75
Gross marginiWhat is left of each dollar of sales after the direct cost of making the product or service.
–
–
73.2%
Operating marginiOperating income as a share of sales: profit from the business before interest and taxes.
–
–
-25.0%
Net marginiNet income as a share of sales: what the owners keep of each dollar sold.
–
–
-18.2%
Return on equityiNet income of the last 12 months divided by shareholders' equity (the average of the latest balance sheet and the one a year earlier): the profit made on the owners' money.
-100%
-58.8%
Free cash flowiCash from operations minus capital spending over the last 12 months: cash the business produced.
-$132.7M
–
CashiCash, cash equivalents and short-term investments on the latest balance sheet.
$197.6M
$98.6M
DebtiShort- and long-term borrowings on the latest balance sheet. Operating leases are not counted.
$0
$0
Net debtiDebt minus cash. Negative means the company holds more cash than it owes (net cash).
-$197.6M (net cash)
-$98.6M
Debt to equityiDebt divided by shareholders' equity on the latest balance sheet: how much is borrowed for each dollar the owners have in the company. Blank when equity is negative.
0.0
0.0
Book value per shareiShareholders' equity (assets minus liabilities) on the latest balance sheet divided by the shares outstanding.
$3.61
P/EiPrice to earnings: market cap divided by net income of the last 12 months. What investors pay for one dollar of yearly profit. Blank when the company made a loss.
loss
19.3
P/SiPrice to sales: market cap divided by revenue of the last 12 months.
–
5.0
EV/SalesiEnterprise value (market cap plus debt minus cash) divided by revenue of the last 12 months.
–
5.0
P/BiPrice to book: market cap divided by shareholders' equity on the latest balance sheet. Blank when equity is negative.
2.1
2.0
Latest = 12 months to 30 Sep 2026; balance-sheet lines at its end. Peer median: companies in the same industry (SIC code), or the sector when the industry is small.
Peers nearest by market cap, its own industry first
Insider Buy/Sell iShares the company's insiders (directors, officers and owners of 10% or more) bought minus what they sold on the open market in the last 90 days, from their Form 4 filings.
–
No data for this company
Institutional holders iThe number of institutional investment managers (13F filers: funds, pensions, asset managers) reporting the stock, compared with the quarter before. 13F reports are public 45 days after quarter end and show long positions only.
-6.6%
156 13F filers vs 167
Institutional ownership iShares held by 13F filers at the latest quarter end, divided by the shares outstanding in the company's latest filing. Above 100% usually means a stale share count or double counting, and is marked.
69%
40.2M shares held by 13F filers (30 Sep 2026) of 58.1M outstanding (9 Nov 2026)
Short interest iShares sold short and not yet bought back, divided by the shares outstanding in the company's latest filing. From FINRA's latest short interest report: FINRA reports twice a month and publishes 7 business days after the settlement date. Above 100% means a stale share count, and is marked.
32%
18.8M shares sold short (30 Oct 2026) of 58.1M outstanding (9 Nov 2026)
Days to cover iShort interest divided by the stock's average daily trading volume, as FINRA publishes it: how many days of normal trading it would take short sellers to buy back every share. Latest report.
7.4
18.8M shares sold short (30 Oct 2026) divided by the stock's average daily volume, as FINRA publishes it
Short interest change iHow the number of shares sold short changed between FINRA's two latest reports, about two weeks apart.
-5.5%
19.9M shares sold short in the report before, 18.8M on 30 Oct 2026
Short sale volume iShare of the stock's latest daily volume on FINRA-reported off-exchange venues that was sold short. Market makers sell short routinely, so 40% to 50% is normal; compare it with the company's own 1-year average in the cell's details. A daily flow, not short interest.
65%
65% of off-exchange volume on 20 Nov 2026 was short sales; 1-year average 52%
Open jobs iJob postings open on the company's own careers site today, where we track it. Blank when we do not track this company's careers site yet.
12
Tracked since 20 Nov 2026
Open jobs change iHow the number of open job postings changed over the last 30 days: total hiring demand, any job, any country. Shown only once we have tracked the company for 30 days.
–
Tracking started 20 Nov 2026; the change shows after 30 days.
Employees iTotal staff the company reported in its latest annual report (10-K), with the change from the year before when both years are reported.
–
No headcount in its annual reports in our data.
Visa hiring (foreign workers) iApplications to hire foreign specialists on H-1B and E-3 visas certified by the Labor Department in the last 12 months, compared with the 12 months before. This is NOT total hiring: most hires need no visa. Open jobs shows total hiring where we track it.
–
No data for this company
Revenue growth iSales in the latest reported quarter compared with the same quarter a year earlier.
–
No data for this company
Capital spending iMoney spent on buildings, machines and equipment in the latest quarter, compared with the same quarter a year earlier.
–
No data for this company
Federal contracts iMoney the US government committed to the company in contracts and grants over the last 12 months.
–
No data for this company
Lobbying iWhat the company reported spending on federal lobbying over the last four quarters.
$110K
4 quarters, $
Layoff notices iWorkers named in state WARN layoff notices over the last 12 months (employers must file them 60 days before a large layoff).
–
No data for this company
News (7d) iArticles about the company published in the last 7 days, from our Google News collection (one search per company, every half hour). Blank when we do not collect news for this company.
70
70 articles in the last 7 days; its usual week has 5 (the median of the 26 weeks before).
News vs usual iArticles in the last 7 days divided by the company's usual week: the median week of the 26 weeks before. Blank when the usual week has fewer than one article.
14×
70 articles in the last 7 days; its usual week has 5.
Unusual now sharp changes in the last 90 days, compared with its own past
First lobbying new, first
Price $7.59 on 20 Nov 2026, +33% over 12 months (12-month range $3.85 to $35.34)
Sharp change
8-K and other filings
Lobbying filing
Insider net buying (open market). Insiders sold a net $8.4M in the last 12 months (the 12 months before: $0).Revenue per quarter. Revenue $11.1M in the latest quarter, -7.9% on a year earlier.Capital spending per quarter. Capital spending $1.8M in the latest quarter, +3145% on a year earlier.Institutional holders (13F filers). 156 13F filers reported holding it in the latest 13F quarter, +42% on a year earlier.Lobbying spend. Lobbying spend: $110K published in the last 12 months (none in the 12 months before).
Every point sits on the day the fact became public (filing acceptance or publication), not the day it happened; prices through 20 Nov 2026. Hover or tap a marker for the fact; click it for the evidence or the source. No data here for: h-1b/e-3 applications certified, federal obligations, workers in warn layoff notices.
12 open postings; careers site tracked since 20 Nov 2026. Most in Legal, policy & compliance 25%, Finance & accounting 17%, People & recruiting 17%, Corporate IT 8%.
Two or more unrelated kinds of records unusual within 30 days
19 May 2026confirmed
Confirmed across sources Institutional holdings and Filings + Financials
Capricor Therapeutics(CAPR): spent $5.1M on capital projects in the quarter ended 31 Mar 2026, 5.7× the same quarter last year, while it saw 59 13F filers open a new position in the quarter ended 31 Mar 2026, 2.0× the same quarter last year. Two unrelated kinds of activity within 5 days.
Financials: Quarterly capital spending jump, became public on 14 May 2026
Institutional holdings: Many funds opening a new position, became public on 15 May 2026
The quarter ended 31 Mar 2026 against the 8 quarters before it.
this quarterearliernormal: $388KSee the evidence (2 changes)
Financials: Quarterly capital spending jump became public on 14 May 2026
Capricor Therapeutics spent $5.1M on capital projects in the quarter ended 31 Mar 2026, 5.7× the same quarter last year.
This period
$5.1M (the quarter ended 31 Mar 2026)
Normal quarter (median of 8 earlier)
$388K
Typical spread (median absolute deviation)
$330K
How far from its usual level
+4.7
Same quarter last year
$896K
History used
3,652 days
the quarter ended 31 Mar 20268 earlier quartersnormal: $388K
Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $5.0M.
Institutional holdings: Many funds opening a new position became public on 15 May 2026
Capricor Therapeutics saw 59 13F filers open a new position in the quarter ended 31 Mar 2026, 2.0× the same quarter last year.
This period
59 (the quarter ended 31 Mar 2026)
Normal quarter (median of 8 earlier)
27
Typical spread (median absolute deviation)
6
How far from its usual level
+3.6
Same quarter last year
29
History used
4,018 days
the quarter ended 31 Mar 20268 earlier quartersnormal: 27
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.
Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.
12 Mar 2024confirmed
Confirmed across sources Filings + Financials and Short interest and volume
Capricor Therapeutics(CAPR): reported revenue of $12.1M for the quarter ended 31 Dec 2023, 13× the same quarter last year, while it had 3.2M shares sold short in the 15 Mar 2024 report, 9.1× the same report last year. Two unrelated kinds of activity within 63 days.
Short interest and volume: Short interest spike, became public on 10 Feb 2024
Short interest and volume: Short interest spike, became public on 28 Feb 2024
Financials: Quarterly revenue change, became public on 12 Mar 2024
Short interest and volume: Short interest spike, became public on 12 Mar 2024
Short interest and volume: Short interest spike, became public on 27 Mar 2024
Short interest and volume: Short interest spike, became public on 10 Apr 2024
The quarter ended 31 Dec 2023 against the 7 quarters before it.
this quarterearliernormal: $1.6MSee the evidence (6 changes)
Short interest and volume: Short interest spike became public on 10 Feb 2024
Capricor Therapeutics had 2.7M shares sold short in the 31 Jan 2024 report, 8.2× the same report last year.
This period
2.7M (the 31 Jan 2024 report)
Normal report (median of 24 earlier)
333K
Typical spread (median absolute deviation)
68K
How far from its usual level
+23.2
Same report last year
328K
History used
2,224 days
the 31 Jan 2024 report24 earlier reportsnormal: 333K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Short interest and volume: Short interest spike became public on 28 Feb 2024
Capricor Therapeutics had 2.7M shares sold short in the 15 Feb 2024 report, 8.6× the same report last year.
This period
2.7M (the 15 Feb 2024 report)
Normal report (median of 24 earlier)
346K
Typical spread (median absolute deviation)
84K
How far from its usual level
+18.6
Same report last year
311K
History used
2,239 days
the 15 Feb 2024 report24 earlier reportsnormal: 346K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Financials: Quarterly revenue change became public on 12 Mar 2024
Capricor Therapeutics reported revenue of $12.1M for the quarter ended 31 Dec 2023, 13× the same quarter last year.
This period
$12.1M (the quarter ended 31 Dec 2023)
Normal quarter (median of 7 earlier)
$1.6M
Typical spread (median absolute deviation)
$1.4M
How far from its usual level
+5.1
Same quarter last year
$960K
History used
4,567 days
the quarter ended 31 Dec 20237 earlier quartersnormal: $1.6M
Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.
Short interest and volume: Short interest spike became public on 12 Mar 2024
Capricor Therapeutics had 2.7M shares sold short in the 29 Feb 2024 report, 8.0× the same report last year.
This period
2.7M (the 29 Feb 2024 report)
Normal report (median of 24 earlier)
377K
Typical spread (median absolute deviation)
120K
How far from its usual level
+13.0
Same report last year
338K
History used
2,253 days
the 29 Feb 2024 report24 earlier reportsnormal: 377K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Short interest and volume: Short interest spike became public on 27 Mar 2024
Capricor Therapeutics had 3.2M shares sold short in the 15 Mar 2024 report, 9.1× the same report last year.
This period
3.2M (the 15 Mar 2024 report)
Normal report (median of 24 earlier)
474K
Typical spread (median absolute deviation)
213K
How far from its usual level
+8.7
Same report last year
353K
History used
2,268 days
the 15 Mar 2024 report24 earlier reportsnormal: 474K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Short interest and volume: Short interest spike became public on 10 Apr 2024
Capricor Therapeutics had 3.5M shares sold short in the 28 Mar 2024 report, 13× the same report last year.
This period
3.5M (the 28 Mar 2024 report)
Normal report (median of 24 earlier)
608K
Typical spread (median absolute deviation)
351K
How far from its usual level
+5.6
Same report last year
275K
History used
2,281 days
the 28 Mar 2024 report24 earlier reportsnormal: 608K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.
Timeline
Changes and notable records, by the date each became public
26 Aug 2026Lobbying change
registered for federal lobbying for the first time in our data (Checkmate Government Relations).
spent $5.1M on capital projects in the quarter ended 31 Mar 2026, 5.7× the same quarter last year, while it saw 59 13F filers open a new position in the quarter ended 31 Mar 2026, 2.0× the same quarter last year. Two unrelated kinds of activity within 5 days.
See the evidence (2 changes)
Financials: Quarterly capital spending jump became public on 14 May 2026
Capricor Therapeutics spent $5.1M on capital projects in the quarter ended 31 Mar 2026, 5.7× the same quarter last year.
This period
$5.1M (the quarter ended 31 Mar 2026)
Normal quarter (median of 8 earlier)
$388K
Typical spread (median absolute deviation)
$330K
How far from its usual level
+4.7
Same quarter last year
$896K
History used
3,652 days
the quarter ended 31 Mar 20268 earlier quartersnormal: $388K
Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $5.0M.
Institutional holdings: Many funds opening a new position became public on 15 May 2026
Capricor Therapeutics saw 59 13F filers open a new position in the quarter ended 31 Mar 2026, 2.0× the same quarter last year.
This period
59 (the quarter ended 31 Mar 2026)
Normal quarter (median of 8 earlier)
27
Typical spread (median absolute deviation)
6
How far from its usual level
+3.6
Same quarter last year
29
History used
4,018 days
the quarter ended 31 Mar 20268 earlier quartersnormal: 27
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.
Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.
15 May 2026Institutional holdings change
saw 59 13F filers open a new position in the quarter ended 31 Mar 2026, 2.0× the same quarter last year.
Same quarter last year: 29; its normal quarter is 27.
See the evidence
This period
59 (the quarter ended 31 Mar 2026)
Normal quarter (median of 8 earlier)
27
Typical spread (median absolute deviation)
6
How far from its usual level
+3.6
Same quarter last year
29
History used
4,018 days
the quarter ended 31 Mar 20268 earlier quartersnormal: 27
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.
spent $5.1M on capital projects in the quarter ended 31 Mar 2026, 5.7× the same quarter last year.
Same quarter last year: $896K; its normal quarter is $388K.
See the evidence
This period
$5.1M (the quarter ended 31 Mar 2026)
Normal quarter (median of 8 earlier)
$388K
Typical spread (median absolute deviation)
$330K
How far from its usual level
+4.7
Same quarter last year
$896K
History used
3,652 days
the quarter ended 31 Mar 20268 earlier quartersnormal: $388K
Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $5.0M.
saw 44 13F filers open a new position in the quarter ended 31 Dec 2024, 8.8× the same quarter last year.
Same quarter last year: 5; its normal quarter is 5.
See the evidence
This period
44 (the quarter ended 31 Dec 2024)
Normal quarter (median of 8 earlier)
5
Typical spread (median absolute deviation)
1
How far from its usual level
+13.0
Same quarter last year
5
History used
3,563 days
the quarter ended 31 Dec 20248 earlier quartersnormal: 5
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.
saw 25 13F filers open a new position in the quarter ended 30 Sep 2024, 6.2× the same quarter last year.
Same quarter last year: 4; its normal quarter is 5.
See the evidence
This period
25 (the quarter ended 30 Sep 2024)
Normal quarter (median of 8 earlier)
5
Typical spread (median absolute deviation)
0.5
How far from its usual level
+6.7
Same quarter last year
4
History used
3,471 days
the quarter ended 30 Sep 20248 earlier quartersnormal: 5
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.
saw 25 13F filers open a new position in the quarter ended 31 Mar 2024, 5.0× the same quarter last year.
Same quarter last year: 5; its normal quarter is 5.
See the evidence
This period
25 (the quarter ended 31 Mar 2024)
Normal quarter (median of 8 earlier)
5
Typical spread (median absolute deviation)
0.5
How far from its usual level
+6.7
Same quarter last year
5
History used
3,288 days
the quarter ended 31 Mar 20248 earlier quartersnormal: 5
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.
had 3.5M shares sold short in the 28 Mar 2024 report, 13× the same report last year.
Same report last year: 275K; its normal report is 608K.
See the evidence
This period
3.5M (the 28 Mar 2024 report)
Normal report (median of 24 earlier)
608K
Typical spread (median absolute deviation)
351K
How far from its usual level
+5.6
Same report last year
275K
History used
2,281 days
the 28 Mar 2024 report24 earlier reportsnormal: 608K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 3.2M shares sold short in the 15 Mar 2024 report, 9.1× the same report last year.
Same report last year: 353K; its normal report is 474K.
See the evidence
This period
3.2M (the 15 Mar 2024 report)
Normal report (median of 24 earlier)
474K
Typical spread (median absolute deviation)
213K
How far from its usual level
+8.7
Same report last year
353K
History used
2,268 days
the 15 Mar 2024 report24 earlier reportsnormal: 474K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
reported revenue of $12.1M for the quarter ended 31 Dec 2023, 13× the same quarter last year, while it had 3.2M shares sold short in the 15 Mar 2024 report, 9.1× the same report last year. Two unrelated kinds of activity within 63 days.
See the evidence (6 changes)
Short interest and volume: Short interest spike became public on 10 Feb 2024
Capricor Therapeutics had 2.7M shares sold short in the 31 Jan 2024 report, 8.2× the same report last year.
This period
2.7M (the 31 Jan 2024 report)
Normal report (median of 24 earlier)
333K
Typical spread (median absolute deviation)
68K
How far from its usual level
+23.2
Same report last year
328K
History used
2,224 days
the 31 Jan 2024 report24 earlier reportsnormal: 333K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Short interest and volume: Short interest spike became public on 28 Feb 2024
Capricor Therapeutics had 2.7M shares sold short in the 15 Feb 2024 report, 8.6× the same report last year.
This period
2.7M (the 15 Feb 2024 report)
Normal report (median of 24 earlier)
346K
Typical spread (median absolute deviation)
84K
How far from its usual level
+18.6
Same report last year
311K
History used
2,239 days
the 15 Feb 2024 report24 earlier reportsnormal: 346K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Financials: Quarterly revenue change became public on 12 Mar 2024
Capricor Therapeutics reported revenue of $12.1M for the quarter ended 31 Dec 2023, 13× the same quarter last year.
This period
$12.1M (the quarter ended 31 Dec 2023)
Normal quarter (median of 7 earlier)
$1.6M
Typical spread (median absolute deviation)
$1.4M
How far from its usual level
+5.1
Same quarter last year
$960K
History used
4,567 days
the quarter ended 31 Dec 20237 earlier quartersnormal: $1.6M
Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.
Short interest and volume: Short interest spike became public on 12 Mar 2024
Capricor Therapeutics had 2.7M shares sold short in the 29 Feb 2024 report, 8.0× the same report last year.
This period
2.7M (the 29 Feb 2024 report)
Normal report (median of 24 earlier)
377K
Typical spread (median absolute deviation)
120K
How far from its usual level
+13.0
Same report last year
338K
History used
2,253 days
the 29 Feb 2024 report24 earlier reportsnormal: 377K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Short interest and volume: Short interest spike became public on 27 Mar 2024
Capricor Therapeutics had 3.2M shares sold short in the 15 Mar 2024 report, 9.1× the same report last year.
This period
3.2M (the 15 Mar 2024 report)
Normal report (median of 24 earlier)
474K
Typical spread (median absolute deviation)
213K
How far from its usual level
+8.7
Same report last year
353K
History used
2,268 days
the 15 Mar 2024 report24 earlier reportsnormal: 474K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Short interest and volume: Short interest spike became public on 10 Apr 2024
Capricor Therapeutics had 3.5M shares sold short in the 28 Mar 2024 report, 13× the same report last year.
This period
3.5M (the 28 Mar 2024 report)
Normal report (median of 24 earlier)
608K
Typical spread (median absolute deviation)
351K
How far from its usual level
+5.6
Same report last year
275K
History used
2,281 days
the 28 Mar 2024 report24 earlier reportsnormal: 608K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.
12 Mar 2024Short interest and volume change
had 2.7M shares sold short in the 29 Feb 2024 report, 8.0× the same report last year.
Same report last year: 338K; its normal report is 377K.
See the evidence
This period
2.7M (the 29 Feb 2024 report)
Normal report (median of 24 earlier)
377K
Typical spread (median absolute deviation)
120K
How far from its usual level
+13.0
Same report last year
338K
History used
2,253 days
the 29 Feb 2024 report24 earlier reportsnormal: 377K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
reported revenue of $12.1M for the quarter ended 31 Dec 2023, 13× the same quarter last year.
Same quarter last year: $960K; its normal quarter is $1.6M.
See the evidence
This period
$12.1M (the quarter ended 31 Dec 2023)
Normal quarter (median of 7 earlier)
$1.6M
Typical spread (median absolute deviation)
$1.4M
How far from its usual level
+5.1
Same quarter last year
$960K
History used
4,567 days
the quarter ended 31 Dec 20237 earlier quartersnormal: $1.6M
Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.
had 2.7M shares sold short in the 15 Feb 2024 report, 8.6× the same report last year.
Same report last year: 311K; its normal report is 346K.
See the evidence
This period
2.7M (the 15 Feb 2024 report)
Normal report (median of 24 earlier)
346K
Typical spread (median absolute deviation)
84K
How far from its usual level
+18.6
Same report last year
311K
History used
2,239 days
the 15 Feb 2024 report24 earlier reportsnormal: 346K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 2.7M shares sold short in the 31 Jan 2024 report, 8.2× the same report last year.
Same report last year: 328K; its normal report is 333K.
See the evidence
This period
2.7M (the 31 Jan 2024 report)
Normal report (median of 24 earlier)
333K
Typical spread (median absolute deviation)
68K
How far from its usual level
+23.2
Same report last year
328K
History used
2,224 days
the 31 Jan 2024 report24 earlier reportsnormal: 333K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 2.7M shares sold short in the 12 Jan 2024 report, 7.8× the same report last year.
Same report last year: 343K; its normal report is 333K.
See the evidence
This period
2.7M (the 12 Jan 2024 report)
Normal report (median of 24 earlier)
333K
Typical spread (median absolute deviation)
68K
How far from its usual level
+23.4
Same report last year
343K
History used
2,205 days
the 12 Jan 2024 report24 earlier reportsnormal: 333K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 2.4M shares sold short in the 29 Dec 2023 report, 6.9× the same report last year.
Same report last year: 341K; its normal report is 333K.
See the evidence
This period
2.4M (the 29 Dec 2023 report)
Normal report (median of 24 earlier)
333K
Typical spread (median absolute deviation)
63K
How far from its usual level
+21.5
Same report last year
341K
History used
2,191 days
the 29 Dec 2023 report24 earlier reportsnormal: 333K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 2.1M shares sold short in the 15 Dec 2023 report, 6.8× the same report last year.
Same report last year: 312K; its normal report is 322K.
See the evidence
This period
2.1M (the 15 Dec 2023 report)
Normal report (median of 24 earlier)
322K
Typical spread (median absolute deviation)
47K
How far from its usual level
+25.7
Same report last year
312K
History used
2,177 days
the 15 Dec 2023 report24 earlier reportsnormal: 322K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 1.5M shares sold short in the 30 Nov 2023 report, 6.1× the same report last year.
Same report last year: 238K; its normal report is 314K.
See the evidence
This period
1.5M (the 30 Nov 2023 report)
Normal report (median of 24 earlier)
314K
Typical spread (median absolute deviation)
40K
How far from its usual level
+19.6
Same report last year
238K
History used
2,162 days
the 30 Nov 2023 report24 earlier reportsnormal: 314K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 1.4M shares sold short in the 15 Nov 2023 report, 5.2× the same report last year.
Same report last year: 261K; its normal report is 311K.
See the evidence
This period
1.4M (the 15 Nov 2023 report)
Normal report (median of 24 earlier)
311K
Typical spread (median absolute deviation)
40K
How far from its usual level
+18.0
Same report last year
261K
History used
2,147 days
the 15 Nov 2023 report24 earlier reportsnormal: 311K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 1.2M shares sold short in the 31 Oct 2023 report, 5.0× the same report last year.
Same report last year: 248K; its normal report is 303K.
See the evidence
This period
1.2M (the 31 Oct 2023 report)
Normal report (median of 24 earlier)
303K
Typical spread (median absolute deviation)
38K
How far from its usual level
+16.4
Same report last year
248K
History used
2,132 days
the 31 Oct 2023 report24 earlier reportsnormal: 303K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 1.2M shares sold short in the 13 Oct 2023 report, 4.1× the same report last year.
Same report last year: 298K; its normal report is 296K.
See the evidence
This period
1.2M (the 13 Oct 2023 report)
Normal report (median of 24 earlier)
296K
Typical spread (median absolute deviation)
34K
How far from its usual level
+18.2
Same report last year
298K
History used
2,114 days
the 13 Oct 2023 report24 earlier reportsnormal: 296K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 669K shares sold short in the 29 Sep 2023 report, 2.0× the same report last year.
Same report last year: 331K; its normal report is 296K.
See the evidence
This period
669K (the 29 Sep 2023 report)
Normal report (median of 24 earlier)
296K
Typical spread (median absolute deviation)
33K
How far from its usual level
+7.5
Same report last year
331K
History used
2,100 days
the 29 Sep 2023 report24 earlier reportsnormal: 296K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 548K shares sold short in the 15 Sep 2023 report, 2.6× the same report last year.
Same report last year: 213K; its normal report is 286K.
See the evidence
This period
548K (the 15 Sep 2023 report)
Normal report (median of 24 earlier)
286K
Typical spread (median absolute deviation)
28K
How far from its usual level
+5.2
Same report last year
213K
History used
2,086 days
the 15 Sep 2023 report24 earlier reportsnormal: 286K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Showing the newest 40 of 79 entries; narrow the window or the kind of data to see older ones.
Not listed: 162 routine records (quarterly and annual reports, results releases, other 8-K items, material agreements and individual insider sales), counted over all history.
Identifiers and sources
How records are matched to this company, and what each source holds for it
Cik
0001133869
Ticker
CAPR
Domain
capricor.com
Employer name
Capricor Therapeutics, Inc. (1 unverified)
Hq location
CA|SAN DIEGO|92121 (1 unverified)
Lobbying client
capricor therapeutics
Name
Capricor Therapeutics Inc, Nile Therapeutics, Inc., SMI PRODUCTS INC
DOL H-1B labor condition applications and PERM certifications11 data points24 Aug 2020 to 15 Mar 2021
Federal lobbying disclosures (LDA)1 record, 3 data points20 Jul 2026 to 30 Sep 2026
SEC Form 13F institutional holdings423 data points31 Mar 2015 to 30 Sep 2026
SEC EDGAR filings (8-K items, S-1, Form D, 10-K/10-Q)171 records22 Feb 2016 to 10 Nov 2026
SEC XBRL company facts (revenue, capex, R&D, backlog...)996 data points4 Jul 2005 to 9 Nov 2026
SEC Form 4 insider transactions33 records, 76 data points18 Mar 2016 to 29 Jun 2026
FINRA short interest (twice monthly)636 data points29 Dec 2017 to 30 Oct 2026
FINRA daily short sale volume (off-exchange)4176 data points1 Aug 2018 to 20 Nov 2026